TGA and ATAGI provisionally approve Novavax (Biocelect Pty Ltd’s) COVID-19 vaccine

Megan Reilly

The Therapeutic Goods Administration (TGA) has granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) for its COVID-19 vaccine, NUVAXOVID for primary vaccination in individuals 18 years of age and older. This is the first protein COVID-19 vaccine to receive regulatory approval in Australia. It is recommended that the vaccine is given in 2 doses administered 3 weeks apart. It is provisionally approved for primary vaccination only at this stage. The full TGA media release is available here. The ATAGI statement is available here.